Lb Pharmaceuticals (LBRX) Accounts Payables (2024 - 2026)

Lb Pharmaceuticals' Accounts Payables history runs 3 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (changed N/A YoY), while the FY2025 annual figure was $2.1 million, down 8.32% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.1 million, up from $2.1 million in the prior quarter.
• The five-year high for Accounts Payables was $7.1 million in Q1 2026, with the low at $2.1 million in Q4 2025.
• The 3-year median for Accounts Payables is $2.5 million (2024), against an average of $3.5 million.
• Peak annual rise in Accounts Payables reached 8.32% in 2025, while the deepest fall reached 8.32% in 2025.
• Lb Pharmaceuticals' Accounts Payables stood at $2.3 million in 2024, then declined by 8.32% to $2.1 million in 2025, then jumped by 234.7% to $7.1 million in 2026.
• Business Quant data shows LBRX's Accounts Payables at $7.1 million in Q1 2026, $2.1 million in Q4 2025, and $2.6 million in Q3 2025.